ArticleJournal of neuro-oncology2026
Retrospective analysis of the impact of antidepressants with anti-acid sphingomyelinase activity on survival of patients with glioblastoma.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlioblastoma (GBM) is the most common malignant primary brain tumor in adults and remains difficult to treat. Though still under investigation, acid sphingomyelinase (ASM) has been implicated in GBM lipid raft formation, which facilitates cancer signaling. We sought to verify if, and if so what kinds of ASM inhibitors (ASMis) improve outcomes in GBM.
methodsWe conducted a retrospective study of GBM patients treated between 2015 and 2024 at one academic center. ASMi impact on overall survival (OS) was assessed using Kaplan-Meier analysis and Cox proportional hazards models adjusting for age, sex, tumor location, use of tumor-treating fields (TTFs), and MGMT promoter methylation status. Propensity score matching was performed to account for baseline imbalances.
resultsASMi use alone was not associated with a statistically significant OS benefit (HR = 0.81, 95% CI 0.55–1.2, p = 0.26). Stratifying by ASMi revealed fluoxetine as the only medication that significantly improved OS (HR = 0.36, 95% CI 0.15–0.9, p = 0.03). In a fluoxetine-only multivariate analysis (n = 17 vs. 186 controls), the survival benefit remained significant (HR = 0.38, 95% CI 0.15–0.94, p = 0.04). This effect persisted in the adjusted propensity-matched cohort (HR = 0.20, 95% CI 0.05–0.78, p = 0.02). Age and unmethylated MGMT promoter status were independently associated with decreased survival.
conclusionFluoxetine was associated with increased survival in GBM patients whereas other ASMis and ASMi use overall was not. These findings suggest that fluoxetine may have unique anti-tumor effects beyond ASM inhibition and justify further investigation.
Indexed as
Identifiers
41483088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.